Mobile

A study looking at 12 weeks treatment with GS-7977 + Ribavirin for patients with chronic genotype 2 or 3 Hepatitis C infection who previously took part in Gilead-sponsored GS-7977 studies in the contr...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-000571-16

A study looking at 12 weeks treatment with GS-7977 + Ribavirin for patients with chronic genotype 2 or 3 Hepatitis C infection who previously took part in Gilead-sponsored GS-7977 studies in the control arms

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of this study are: • To determine the efficacy of GS-7977 + RBV as measured by the proportion of subjects with sustained viral response at 12 weeks after discontinuation of therapy (SVR12). • To evaluate the safety and tolerability of GS-7977 + RBV as assessed by review of the accumulated safety data.

Critère d'inclusion

  • Chronic Genotype 2 or 3 HCV Infection

Liens